Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Published Time:
2021-03-12 17:39
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
IBD encompasses chronic, non-specific inflammatory conditions of the gut, primarily ulcerative colitis (UC) and Crohn's disease (CD). Clinical manifestations include diarrhea, abdominal pain, and even bloody stools. UC can occur at any age, with peaks between 15-30 and 50-70 years old. It primarily affects the rectum and sigmoid colon, exhibiting diffuse distribution. CD can also occur at any age but is most common in adolescence. Lesions can affect the entire gastrointestinal tract from mouth to anus, characterized by segmental and skip lesions, most frequently involving the terminal ileum, colon, or both the small and large intestine. Both UC and CD are chronic inflammatory diseases currently without a cure, requiring lifelong medication management. Often termed "incurable intestinal disorders," they carry high relapse rates of 70–90%. The incidence of IBD in China is steadily increasing, establishing it as a common and challenging condition within the digestive system. It represents a key focus and significant challenge in both basic research and clinical diagnosis/treatment of digestive diseases.
Janus kinases (JAKs) comprise a family of tyrosine kinases, consisting of four members: JAK1, JAK2, JAK3, and TYK2. JAKs play crucial roles in signal transduction for numerous cytokines. Together with their downstream effectors, Signal Transducers and Activators of Transcription (STATs), they mediate cytokine receptor regulation of nuclear gene transcription and expression. Dysfunction of the JAK-STAT signaling pathway is closely associated with the pathogenesis of hematological diseases such as polycythemia vera, thrombocythemia, leukemia, and myelofibrosis, as well as autoimmune disorders including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), IBD, and atopic dermatitis. Consequently, the JAK kinase family has emerged as a critical therapeutic target for these conditions.
About VC005
VC005 is a novel, potent, gut-restricted selective JAK1 inhibitor independently developed by Jiangsu Vcare. It features controllable systemic exposure coupled with high intestinal exposure. Preclinical studies have demonstrated that VC005 exhibits a low effective dose, high tolerated dose, and minimal side effects in animal models, offering dual advantages of safety and efficacy. It holds promise as a potential globally leading gut-selective anti-inflammatory drug.
Related News
28
2025
/
11
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced that the Phase II clinical study of VC005 topical gel, a self-developed second-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD) in adults in China has successfully completed unblinding and preliminary analysis, yielding positive results.
View Details
11
2025
/
11
Recently, Eratrectinib (VC004), a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), was included in the " Support Anti-tumor drugR&D for Kids (SPARK Plan)" launched by the CDE of the NMPA, become the 5th innovative drug variety in the country to be included in this program. This important progress will accelerate the R&D process of the domestic new anticancer drug Eratrectinib in the field of pediatric oncology, bringing new hope to pediatric oncology patients in China.
View Details
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn